185 related articles for article (PubMed ID: 9328317)
1. Critical role of Fas/Fas ligand interaction in CD28-independent pathway of allogeneic murine hepatocyte rejection.
Kawahara T; Kasai S; Yagita H; Sawa M; Kato K; Azuma M; Nakajima A; Okumura K; Futagawa S; Mito M
Hepatology; 1997 Oct; 26(4):944-8. PubMed ID: 9328317
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hepatocyte transplantation: contribution of Fas-Fas ligand interaction to allogeneic hepatocyte rejection.
Kawahara T; Yagita H; Kasai S; Sawa M; Kato K; Okumura K; Futagawa S; Mito M
J Gastroenterol Hepatol; 1998 Sep; 13 Suppl():S119-23. PubMed ID: 9792045
[TBL] [Abstract][Full Text] [Related]
3. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
4. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
[TBL] [Abstract][Full Text] [Related]
5. Fas system-mediated apoptosis suppresses lymphopoiesis.
Yasutomo K; Nagasawa H; Hisaeda H; Good RA; Kuroda Y; Himeno K
J Immunol; 1996 Sep; 157(5):1981-6. PubMed ID: 8757318
[TBL] [Abstract][Full Text] [Related]
6. The role of Fas ligand as an effector molecule in corneal graft rejection.
Stuart PM; Yin X; Plambeck S; Pan F; Ferguson TA
Eur J Immunol; 2005 Sep; 35(9):2591-7. PubMed ID: 16114107
[TBL] [Abstract][Full Text] [Related]
7. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
Winter H; Hu HM; Urba WJ; Fox BA
J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
[TBL] [Abstract][Full Text] [Related]
9. Protection of islet allografts transplanted together with Fas ligand expressing testicular allografts.
Takeda Y; Gotoh M; Dono K; Nishihara M; Grochowiecki T; Kimura F; Yoshida T; Ohta Y; Ota H; Ohzato H; Umeshita K; Takeda T; Matsuura N; Sakon M; Kayagaki N; Yagita H; Okumura K; Miyasaka M; Monden M
Diabetologia; 1998 Mar; 41(3):315-21. PubMed ID: 9541172
[TBL] [Abstract][Full Text] [Related]
10. Ca2+-dependent, Fas- and perforin-independent apoptotic death of allografted tumor cells by a type of activated macrophage.
Yoshida R; Sanchez-Bueno A; Yamamoto N; Einaga-Naito K
J Immunol; 1997 Jul; 159(1):15-21. PubMed ID: 9200433
[TBL] [Abstract][Full Text] [Related]
11. Perforin- and Fas-mediated cytotoxic pathways are not required for allogeneic resistance to bone marrow grafts in mice.
Baker MB; Podack ER; Levy RB
Biol Blood Marrow Transplant; 1995 Dec; 1(2):69-73. PubMed ID: 9118294
[TBL] [Abstract][Full Text] [Related]
12. Antigen-induced cell death of T effector cells in vitro proceeds via the Fas pathway, requires endogenous interferon-gamma and is independent of perforin and granzymes.
Sobek V; Balkow S; Körner H; Simon MM
Eur J Immunol; 2002 Sep; 32(9):2490-9. PubMed ID: 12207333
[TBL] [Abstract][Full Text] [Related]
13. A major role for the Fas pathway in acute graft-versus-host disease.
Via CS; Nguyen P; Shustov A; Drappa J; Elkon KB
J Immunol; 1996 Dec; 157(12):5387-93. PubMed ID: 8955186
[TBL] [Abstract][Full Text] [Related]
14. Accelerated rejection of Fas ligand-expressing heart grafts.
Takeuchi T; Ueki T; Nishimatsu H; Kajiwara T; Ishida T; Jishage K; Ueda O; Suzuki H; Li B; Moriyama N; Kitamura T
J Immunol; 1999 Jan; 162(1):518-22. PubMed ID: 9886428
[TBL] [Abstract][Full Text] [Related]
15. Fas-mediated cytotoxicity is not required for rejection of murine nonvascularized heterotopic cardiac allografts.
Djamali A; Odorico JS
Transplantation; 1998 Dec; 66(12):1793-801. PubMed ID: 9884278
[TBL] [Abstract][Full Text] [Related]
16. Fas involvement in cytotoxicity mediated by human NK cells.
Montel AH; Bochan MR; Hobbs JA; Lynch DH; Brahmi Z
Cell Immunol; 1995 Dec; 166(2):236-46. PubMed ID: 7497525
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of Fas and the costimulatory molecules B7-1 and B7-2 on peripheral lymphocytes in autoimmune B6/gld mice.
Weintraub JP; Eisenberg RA; Cohen PL
J Immunol; 1997 Oct; 159(8):4117-26. PubMed ID: 9379003
[TBL] [Abstract][Full Text] [Related]
18. Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation.
Lu L; Qian S; Hershberger PA; Rudert WA; Lynch DH; Thomson AW
J Immunol; 1997 Jun; 158(12):5676-84. PubMed ID: 9190916
[TBL] [Abstract][Full Text] [Related]
19. The role of the antigen-presenting cell in Fas-mediated direct and bystander killing: potential in vivo function of Fas in experimental allergic encephalomyelitis.
Thilenius AR; Sabelko-Downes KA; Russell JH
J Immunol; 1999 Jan; 162(2):643-50. PubMed ID: 9916681
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells.
Sayers TJ; Brooks AD; Lee JK; Fenton RG; Komschlies KL; Wigginton JM; Winkler-Pickett R; Wiltrout RH
J Immunol; 1998 Oct; 161(8):3957-65. PubMed ID: 9780164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
